Signal detection of drospirenone-containing oral contraceptives: a disproportionality analysis using the Korea Adverse Event Reporting System Database, 2008-2017

被引:3
作者
Lee, Yeri [1 ]
Choi, Ahhyung [1 ]
Noh, Yunha [1 ]
Jeon, Ha-Lim [1 ]
Choe, Seung-Ah [2 ]
Shin, Ju-Young [1 ,3 ]
机构
[1] Sungkyunkwan Univ, Sch Pharm, Suwon, South Korea
[2] Korea Univ, Coll Med, Dept Prevent Med, Seoul, South Korea
[3] Samsung Adv Inst Hlth Sci & Technol, Dept Clin Res Design & Evaluat, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
adverse events; gynaecology; epidemiology; DRUG-REACTIONS; RISK;
D O I
10.1136/bmjopen-2020-045948
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To detect the signals for drospirenone-containing oral contraceptives (DCOCs) and describe the reporting pattern of adverse events (AEs) caused by DCOCs compared with levonorgestrel/desogestrel/gestodene-containing (second/third generation) oral contraceptives. Design A descriptive analysis of claims data. Setting The Korea Institute of Drug Safety & Risk Management-Korea Adverse Event Reporting System Database from 1 February 2008 to 31 December 2017. Outcome measures Signals for DCOCs were identified using three data mining indices. The characteristics, death cases, and the annual pattern of AE reports were compared between DCOCs and second/third generation oral contraceptives. Results Of the 242 DCOC-related AEs, 54 signals were detected and 10 were identified as new signals that were not included in Korea, US and UK label. The newly detected signals include deep vein thrombophlebitis and frequent urination. Serious AEs were more likely to be reported with DCOCs (7.85%) than with second/third generation oral contraceptives (2.92%). Five deaths after use of DCOCs were reported with vascular AEs, such as pulmonary embolism and thrombosis, whereas one death after use of second/third generation oral contraceptives was reported with the cardiac arrest. Conclusions We identified 10 new signals related to DCOCs that were not included in the current label. Additionally, we found higher reports of the deaths and vascular AEs associated with DCOCs than with second/third generation oral contraceptives, which warrants careful monitoring to ensure the safe use of DCOCs.
引用
收藏
页数:9
相关论文
共 31 条
[1]   Under-reporting of adverse drug reactions -: Estimate based on a spontaneous reporting scheme and a sentinel system [J].
Alvarez-Requejo, A ;
Carvajal, A ;
Bégaud, B ;
Moride, Y ;
Vega, T ;
Arias, LHM .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (06) :483-488
[2]   Quantitative signal detection using spontaneous ADR reporting [J].
Bate, A. ;
Evans, S. J. W. .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2009, 18 (06) :427-436
[3]   History of oral contraceptive drugs and their use worldwide [J].
Christin-Maitre, Sophie .
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 27 (01) :3-12
[4]   A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception [J].
Dragoman, Monica V. ;
Tepper, Naomi K. ;
Fu, Rongwei ;
Curtis, Kathryn M. ;
Chou, Roger ;
Gaffield, Mary E. .
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2018, 141 (03) :287-294
[5]   Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports [J].
Evans, SJW ;
Waller, PC ;
Davis, S .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2001, 10 (06) :483-486
[6]  
GOLDZIEHER JW, 1971, FERTIL STERIL, V22, P609
[7]   Practical pharmacovigilance analysis strategies [J].
Gould, AL .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2003, 12 (07) :559-574
[8]  
Group E.E.W, 2006, GUID US STAT SIGN DE GUID US STAT SIGN DE
[9]   Performance of Pharmacovigilance Signal-Detection Algorithms for the FDA Adverse Event Reporting System [J].
Harpaz, R. ;
DuMouchel, W. ;
LePendu, P. ;
Bauer-Mehren, A. ;
Ryan, P. ;
Shah, N. H. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 (06) :539-546
[10]  
Korea Institute of Drug Safety Risk Management, 2018, MAN US KOR I DRUG SA MAN US KOR I DRUG SA